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Abstract: Background: The GRPR-antagonist 68Ga-SB3 visualized prostate cancer lesions in animal
models and in patients. Switching radiometal from 68Ga to 111In impaired tumor targeting in
mice, but coinjection of the neprilysin (NEP)-inhibitor phosphoramidon (PA) stabilized 111In-SB3 in
circulation and remarkably increased tumor uptake. We herein report on the biological profile of
111In-SB4: 111In-[DAla11]SB3. Methods: The biological responses of 111In-SB3/SB4 were compared in
PC-3 cells and animal models. Results: Gly11/DAla11-replacement deteriorated GRPR-affinity (SB4
IC50: 10.7 ± 0.9 nM vs. SB3 IC50: 4.6 ± 0.3 nM) and uptake in PC-3 cells (111In-SB4: 1.3 ± 0.4% vs.
111In-SB3 16.2 ± 0.8% at 1 h). 111In-SB4 was more stable than 111In-SB3, but PA-coinjection stabilized
both radiotracers in peripheral mice blood. Unmodified 111In-SB3 showed higher uptake in PC-3
xenografts (8.8 ± 3.0%ID/g) vs. 111In-SB4 (3.1 ± 1.1%ID/g) at 4 h pi. PA-coinjection improved tumor
uptake, with 111In-SB3 still showing superior tumor targeting (38.3 ± 7.9%ID/g vs. 7.4 ± 0.3%ID/g
for 111In-SB4). Conclusions: Replacement of Gly11 by DAla11 improved in vivo stability, however,
at the cost of GRPR-affinity and cell uptake, eventually translating into inferior tumor uptake of
111In-SB4 vs. unmodified 111In-SB3. On the other hand, in-situ NEP-inhibition turned out to be
a more efficient and direct strategy to optimize the in vivo profile of 111In-SB3, and potentially other
peptide radiotracers.
Keywords: GRPR-antagonist; bombesin-like radioligand; tumor targeting; tumor imaging; neprilysin-
inhibition; phosphoramidon; in vivo stability
1. Introduction
The gastrin-releasing peptide receptor (GRPR) has attracted much attention in cancer diagnosis
and therapy [1–4]. High levels of GRPR expression have been documented in a variety of human
cancers, including prostate, breast and lung cancer, as opposed to lack of expression in healthy
surrounding tissue [5–10]. This combination renders GRPR an appealing biomolecular target for
directing diagnostic/therapeutic radionuclide-carriers specifically onto cancer lesions in a personalized
theranostic approach. Based on the GRPR natural ligands, bombesin (BBN), gastrin-releasing peptide
(GRP) and its C-terminal fragments (e.g., GRP(17–27) or neuromedin C, NMC), several peptide analogs
have been developed by strategic structural interventions to allow for stable binding of the desired
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radionuclide and aim at biological profiles promising for clinical translation [4]. Yet, such agonist-based
radioligands activate the GRPR upon binding, eliciting side effects after injection to patients. Recently
a shift of paradigm has occurred toward radiolabeled GRPR-antagonists that, besides their higher
inherent biosafety, have unexpectedly shown superior tumor targeting and faster background clearance
from the body compared to agonists [11,12].
As a part of our work on GRPR-directed theranostic agents, we have developed a series of radiolabeled
analogs based on the potent GRPR-radioantagonist [DPhe6,Leu13-NHEt]BBN(6-13) [11,13–15]. Accordingly,
SB3 was generated by coupling the universal DOTA chelator to its N-terminal DPhe6 via a suitable linker
(SB3 = DOTA-p-aminomethylaniline-diglycolic acid-DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-NHEt; Figure 1a),
thereby allowing for labeling with SPECT (111In), PET (68Ga) and beta-emitting (177Lu) radionuclides for
eventual theranostic clinical use [16–18]. The 68Ga-SB3 radiotracer in particular, was successful in visualizing
50% of prostate and breast cancer lesions in patients with advanced disease applying PET/CT [16].
In a following study including 10 therapy-naïve primary prostate cancer patients, lesion visualization with
68Ga-SB3 was successful in 90% of the cases. Most importantly, a significant correlation could be established
between the intensity of uptake in the lesions and the GRPR-expression levels [19]. Surprisingly however,
the theranostic prospects with SB3 were found compromised when switching radiometal from 68Ga to 111In
or 177Lu. In preclinical studies, 111In/177Lu-SB3 displayed drastically impaired tumor localization levels
compared to 68Ga-SB3, a result attributed to impaired metabolic stability of the 111In/177Lu-radiopeptides
in mice. This result could be banned by coinjection of the neprilysin (NEP)-inhibitor phosphoramidon (PA),
that stabilized 111In/177Lu-SB3 in peripheral mouse blood and remarkably improved tumor uptake [17].
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Figure 1. (a) Chemical structure of SB3 (Xaa11 = Gly, R = H) and SB4 (Xaa11 = DAla, R = CH3); (b) Typical 
radiochromatogram of HPLC analysis of 111In-SB4 labeling reaction mixture, showing quantitative 
formation of the high purity radioligand eluting at tR= 17.6 min (HPLC system 1). 
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The respective half-maximal inhibitory concentration (IC50) values differed, yielding the following 
rank of increasing receptor affinity: SB4 (IC50 = 11.2 ± 1.1 nM, n = 3) < SB3 (IC50 = 4.6 ± 0.3 nM, n=3) < 
[Tyr4]BBN (IC50 = 1.3 ± 0.1 nM, n = 5). Hence, single Gly11/DAla11-replacement in the SB3 peptide chain 
caused a significant drop of binding affinity of SB4 to GRPR (P<0.001). 
2.2.2. Comparative Uptake of 111In-SB3 and 111In-SB4 by PC-3 Cells 
During 1 h incubation at 37 °C in PC-3 cells, 111In-SB3 and 111In-SB4 were taken up by the cells 
via a GRPR-mediated process, as demonstrated by the drop of cell uptake in the presence of excess 
[Tyr4]BBN (Figure 2b). In both cases, the bulk of radioactivity remained bound to the cell-membrane 
with only a small portion internalizing into the cells, as consistent with a radioantagonist profile [11]. 
However, 111In-SB4 showed much lower overall uptake in PC-3 cells (1.9 ± 0.5% of total added 
activity) vs. 111In-SB3 (16.2±0.8% of total added activity; P<0.0001), further demonstrating the negative 
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Figure 1. (a) Chemical structure of SB3 (Xaa11 = Gly, R = H) and SB4 (Xaa11 = DAla, R = CH3); (b) Typical
radiochromatogram of HPLC analysis of 111In-SB4 labeling reaction mixture, showing quantitative
formation of the high purity radioligand eluting at tR = 17.6 min (HPLC system 1).
Ea lier work on the development of GRPR-antagonists generated a solid body of structure-activity
relationships data, pinpointing at important factors for sustained in vivo action [12,20]. Metabolic
stability was found to be a key prerequisite for sufficient delivery to GRPR-expressing cells and
prolonged in vivo responses. Metabolic stability could be enhanced by suitable structural modifications,
including DAla11/Gly11 in BBN-based or DAla24/Gly24 in GRP-based peptide ligands [20,21]. Interestingly,
we made similar observations in a series of 99mTc-labeled [DPhe6,Leu13-NHEt]BBN(6-13) analogs, carrying
Molecules 2019, 24, 1015 3 of 11
an acyclic tetraamine chelator at the N-terminus. Thus, 99mTc-[N4-p-aminomethylaniline-diglycolic
acid-DPhe6,DAla11,Leu13-NHEt]BBN(6-13) displayed the highest metabolic stability within this small library
of compounds [22].
In the present work we have compared the two stabilization strategies, namely the structural
DAla11/Gly11-substitution in the peptide sequence vs. the in situ NEP-inhibition approach [23],
for their efficacy to improve tumor uptake and overall pharmacokinetics of resulting 111In-radiotracers
in mice. For this purpose, we first developed SB4, [DAla11]SB3, and directly compared the in vitro
and in vivo behavior of 111In-SB4 vs. 111In-SB3 in the same experimental models. We next studied
the impact of NEP-inhibition after PA-coinjection on the in vivo stability and the tumor targeting
capabilities of the two 111In-radiotracers.
2. Results
2.1. Peptides and Radioligands
The new SB4 peptide conjugate was generated by single Gly11/DAla11-replacement in
the SB3 peptide chain (Figure 1a). Both SB3 and SB4 carrying the universal chelator DOTA
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) at their N-terminus could be labeled with
111In at molecular activities of 3.7–7.4 MBq 111In/nmol peptide. Quality control by radioanalytical
HPLC demonstrated in all cases labeling yields >98% in a >96% radiochemical purity. Hence,
the resultant 111In-SB3 and 111In-SB4 radioligands were used without further purification in all
subsequent experiments. A representative radiochromatogram of analysis of labeling reaction product
111In-SB4 is included in Figure 1b.
2.2. In Vitro Assays in PC-3 Cells
2.2.1. Affinity of SB3 and SB4 for the GRPR
As shown in Figure 2a, SB3, SB4 as well as the [Tyr4]BBN reference were able to displace
[125I-Tyr4]BBN from GRPR-sites on PC-3 cell membranes in a monophasic and dose-dependent manner.
The respective half-maximal inhibitory concentration (IC50) values differed, yielding the following
rank of increasing receptor affinity: SB4 (IC50 = 11.2 ± 1.1 nM, n = 3) < SB3 (IC50 = 4.6 ± 0.3 nM, n = 3)
< [Tyr4]BBN (IC50 = 1.3 ± 0.1 nM, n = 5). Hence, single Gly11/DAla11-replacement in the SB3 peptide
chain caused a significant drop of binding affinity of SB4 to GRPR (p < 0.001).
2.2.2. Comparative Uptake of 111In-SB3 and 111In-SB4 by PC-3 Cells
During 1 h incubation at 37 ◦C in PC-3 cells, 111In-SB3 and 111In-SB4 were taken up by the cells
via a GRPR-mediated process, as demonstrated by the drop of cell uptake in the presence of excess
[Tyr4]BBN (Figure 2b). In both cases, the bulk of radioactivity remained bound to the cell-membrane
with only a small portion internalizing into the cells, as consistent with a radioantagonist profile [11].
However, 111In-SB4 showed much lower overall uptake in PC-3 cells (1.9± 0.5% of total added activity)
vs. 111In-SB3 (16.2 ± 0.8% of total added activity; p < 0.0001), further demonstrating the negative
impact of the Gly11/DAla11-substitution on the interaction ability of the forming radiotracer with
the GRPR.
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22 °C by  SB4 (IC50 11.2 ± 1.1 nM, n = 3),  SB3 (IC50 4.6 ± 0.3 nM, n=3) and  [Tyr4]BBN (IC50 1.3 ± 
0.1 nM, n = 5); (b) Non-specific and GRPR-specific association of 111In-SB3 (blue) and 111In-SB4 (red) in 
PC-3 cells after 1 h incubation at 37 °C. Results represent average cell associated activity ± sd (solid 
bars: membrane bound; checkered bars: internalized) vs. total-added activity (n = 4, in triplicate); non-
specific values were obtained in the presence of 1 μM [Tyr4]BBN and were subtracted from totals to 
provide the specific values; the study was conducted with PC-3 cells as confluent monolayers. 
2.3. In Vivo Comparison of 111In-SB3 and 111In-SB4 
2.3.1. Stability of 111In-SB3 and 111In-SB4 in Healthy Mice 
The two 111In-SB3 and 111In-SB4 radiotracers exhibited different metabolic stability in peripheral 
mouse blood. As revealed by HPLC analysis of blood samples collected from mice at 5 min after 
radioligand injection, the DAla11-substituted 111In-SB4 was markedly more stable (80 ± 3% intact, n = 
3) than non-modified 111In-SB3 (56 ± 2% intact, n = 3; P<0.001), revealing the positive influence of the 
adopted structural intervention on metabolic stability; representative radiochromatograms for 111In-
SB3 and 111In-SB4 are shown in Figure 3a, b, respectively.  
Figure 3. Radiochromatograms of HPLC analysis of mouse blood samples collected 5 min pi, of (a) 
111In-SB3 (55% intact radiotracer) or (b) 111In-SB4 (77% intact radiotracer) without PA-coinjection; the 
respective radiochromatograms of (c) 111In-SB3 (98.9% intact radiotracer), or (d) 111In-SB4 (99.7% intact 
radiotracer) with PA-coinjection are also included; the tR of parent radiopeptide was determined by 
coinjection with the respective radioligand sample in the column (HPLC system 2) and is indicated 
here by the arrow. 
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Figure 2. (a) [125I-Tyr4]BBN displacement curves from GRPR-sites on PC-3 cells after 1 h incubation at
22 ◦C by  SB4 (IC50 11.2 ± 1.1 nM, n = 3), • SB3 (IC50 4.6 ± 0.3 nM, n = 3) and [Tyr4]BBN (IC50 1.3
± 0.1 nM, n = 5); (b) Non-specific and GRPR-specific association of 111In-SB3 (blue) and 111In-SB4 (red)
in PC-3 cells after 1 h incubation at 37 ◦C. Results represent average cell associated activity ± sd (solid
bars: membrane bound; checkered bars: internalized) vs. total-added activity (n = 4, in triplicate);
non-specific values were obtained in the presence of 1 µM [Tyr4]BBN and were subtracted from totals
to provide the specific values; the study was conducted with PC-3 cells as confluent monolayers.
2.3. In Vivo Comparison of 111In-SB3 and 111In-SB4
2.3.1. Stability of 111In-SB3 and 111In-SB4 in Healthy Mice
The two 111In-SB3 and 111In-SB4 radiotracers exhibited different metabolic stability in peripheral
mouse blood. As revealed by HPLC analysis of blood samples collected from mice at 5 min after
radioligand injection, the DAla11-substituted 111In-SB4 was markedly more stable (80 ± 3% intact,
n = 3) than non-modified 111In-SB3 (56 ± 2% intact, n = 3; p < 0.001), revealing the positive influence
of the adopted structural intervention on metabolic stability; representative radiochromatograms for
111In-SB3 and 111In-SB4 are shown in Figure 3a,b, respectively.
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Figure 3. Radioc ro t r f PLC analysis of mouse blood samples coll cted 5 min pi,
of (a) 111In-SB3 (55% intact radiotracer) or (b) 111In-SB4 (77% intact radiotracer) without PA-coinjection;
the respective radiochromatograms of (c) 111In-SB3 (98.9% intact radiotracer), or (d) 111In-SB4
(99.7% intact radiotracer) with PA-coinjection are also included; the tR f arent radiopeptide was
determined by coinjecti with the respective radioligand sample in the column (HPLC system 2) and
is i dicated here by the arrow.
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It is interesting to note that coinjection of the NEP-inhibitor PA stabilized both 111In-SB3 and
111In-SB4 in mouse circulation (Figure 3c,d, respectively; p < 0.001), revealing NEP as the major
degrading protease in vivo. Hence, the in-situ NEP-inhibition strategy turned out to be more efficacious
in metabolically stabilizing the radioligand than the structural modification approach, pursued herein
via Gly11/DAla11-replacement.
2.3.2. Comparative Biodistribution of 111In-SB3 and 111In-SB4 in SCID Mice Bearing PC-3 Xenografts
The biodistribution of 111In-SB3 and 111In-SB4 was studied in severe combined immune deficiency
(SCID) mice bearing human PC-3 xenografts expressing the GRPR. Subcutaneous tumors of suitable
size developed in the flanks of mice about four weeks after inoculation of a suspension of prostate
adenocarcinoma PC-3 cells and biodistribution was conducted. Comparative tissue distribution results,
expressed as percent injected dose per gram (%ID/g) and presented as average %ID/g ± sd (n = 4),
are included in Figure 4a for 111In-SB3 and Figure 4b for 111In-SB4.
Molecules 2019, 24, x FOR PEER REVIEW 5 of 11 
 
It s interesting to n te that coinjection of the NEP-inhibitor PA stabilized both 111In-SB3 and 
111In-SB4 in mouse circulation (Figure 3 , d, res ectively; P<0.001), revealing NEP s the major 
degrading protease in vivo. Hence, the in-situ NEP-inhibition strategy tu n d out to be more 
efficacious in me abolically stabilizi g the radioligand than the structural modification approach, 
pursued herein via Gly11/DAla11-replacement. 
2.3.2. Comparative Biodistribution of 111In-SB3 and 111In-SB4 in SCID Mice Bearing PC-3 Xenografts 
The bi distribution of 111In-SB3 and 111In-SB4 was studied in severe combined immune 
d ficiency (SCID) mice bearing human PC-3 xenografts expressing the GRPR. Subc taneous tumors 
of suitable size developed in the flanks of mice about fo r weeks after inoculation of a suspension of 
pr st te adenoc rcinoma PC-3 cells and biodistribution was conduc ed. Comparative tissue 
di tribution results, expressed as percent injected dose per gr m (%ID/g) and prese ted as average 
%ID/g±sd (n = 4), are included in  a  1In-SB3 and Figure 4b for 111In-SB4. 
 
(a) 
(b) 
 
  
Figure 4. Biodistribution data for (a) 111In-SB3 or (b) 111In-SB4 in SCID mice bearing subcutaneous PC-
3 xenografts in their flanks at 4 and 24 h pi; two additional animal groups at the 4 h pi interval 
comprise mice coinjected with excess [Tyr4]BBN for GRPR-blockade (block) or a 300 μg dose of PA 
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Both tracers showed rapid blood clearance with quite similar distribution patterns in all non-
GRPR-expressing tissues at all time points. The radioactivity cleared from the body of mice via the 
kidneys and the urinary tract. However, significant differences in the uptake of the two tracers were 
evident in the PC-3 tumors and the tissues physiologically expressing the GRPR, such as the pancreas. 
Figure 4. Biodistribution data for (a) 111In-SB3 or (b) 111In-SB4 in SCID mice bearing subcutaneous
PC-3 xenografts in their flanks at 4 and 24 h pi; two additional animal groups at the 4 h pi interval
comprise mice coinjected with excess [Tyr4]BBN for GRPR-blockade (block) or a 300 µg dose of PA for
in situ inhibition of NEP (PA). Data is expressed as average ± sd %ID/g, n = 4 and plots were drawn
in the same scale of uptake for easy comparison; statistically significant differences are indicated by
** or ++ between controls and block or PA groups, respectively, at 4 h pi, as estimated by one-way
ANOVA with Tukey’s post-hoc analysis. Bl = blood, Li = liver, He = heart, Ki = kidneys, St = stomach,
In = intestine, Sp = spleen, Mu = muscle, Lu = lungs, Fe = femur, Pa = pancreas and Tu = PC-3 tumor.
Both tracers showed rapid blood clearance with quite similar distribution patterns in all
non-GRPR-expressing tissues at all time points. The radioactivity cleared from the body of mice
via the kidneys and the urinary tract. However, significant differences in the uptake of the two tracers
were evident in the PC-3 tumors and the tissues physiologically expressing the GRPR, such as the
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pancreas. Thus, tumor uptake of non-modified 111In-SB3 were 8.8 ± 3.0%ID/g at 4 h pi declining to
4.4 ± 0.3%ID/g at 24 h pi, whereas the respective values for 111In-SB4 were 3.0 ± 0.8%ID/g (p < 0.01)
and 0.9 ± 0.1%ID/g (p < 0.0001). Likewise, 111In-SB3 exhibited higher pancreatic uptake compared
to 111In-SB4 both at 4 h pi (3.5 ± 0.4%ID/g and 1.6 ± 0.8%ID/g, respectively; p < 0.01) and at 24 h
(0.6 ± 0.1%ID/g and 0.1 ± 0.0%ID/g, respectively; p < 0.001). It should be noted that tumor and
pancreas values achieved by 111In-SB4 at 4 h pi were significantly reduced after coinjection of excess
[Tyr4]BBN, suggesting a GRPR-mediated uptake (p < 0.001). For 111In-SB3 however, no significant
change was found adopting the one way ANOVA test with Tukey’s post-hoc analysis due to the wide
variance of values and the unpaired two tailed Student’s t test was additionally conducted revealing
highly significant differences (p < 0.001).
The effect of metabolic stabilization of both radiotracers during NEP-inhibition was studied
in separate animal groups co-injected with a 300 µg dose of PA. As a result, the tumor uptake was
markedly improved for both radioligands, but was most affected in the case of unmodified 111In-SB3
compared to the more in vivo robust 111In-SB4. Thus, in the case of 111In-SB3 a 4.3-fold enhancement of
tumor uptake was accomplished at 4 h pi by PA coinjection (38.3± 7.9%ID/g – PA - vs. 8.8± 3.0%ID/g
– control; p < 0.001) with only 2.4-fold improvement achieved for 111In-SB4 (7.3 ± 0.3%ID/g – PA – vs.
3.0 ± 0.8%ID/g – control; p < 0.001). Likewise, higher enhancement was observed in the uptake of
111In-SB3 compared to 111In-SB4 after PA-coinjection in all tissues with physiological GRPR-expression,
especially in the mouse pancreas (33.1 ± 6.2%ID/g vs. 4.9 ± 0.7%ID/g, respectively; p < 0.001).
3. Discussion
Radiotracers based on GRPR-antagonists have been lately attracting much attention in nuclear medicine
compared to agonists, largely because of their higher inherent biosafety [11,12]. First radioligands developed
for nuclear medicine purposes were based on linear native BBN-/GRP-sequences, which, following systemic
administration and subsequent GRPR-binding, internalized into target cells while at the same time activating
the receptor and eliciting adverse effects [2–4]. In contrast, radiolabeled GRPR-antagonists, that neither
internalize nor activate the GRPR upon binding, turned out to be more appropriate for human use [20].
Moreover, recent studies have shown that radiolabeled GRPR-antagonists unexpectedly achieved superior
tumor targeting and better pharmacokinetics compared to their agonist counterparts [12]. It should be noted
that GRPR-antagonists are actually synthetic compounds designed to inhibit the action of agonists in the
body, preferably for long periods of time. Accordingly, they are tailored to better resist in vivo degradation
through strategic chemical changes of their structure, as for example by introduction of unnatural amino
acids, reduction or methylation of amide bonds and other means [20]. It is therefore, reasonable to assume
that radiolabeled GRPR-antagonists for nuclear medicine use would also be more stable than agonists.
Following this rationale, we have been exploring the impact of in vivo metabolic stability
on the biological profile of radiolabeled GRPR-antagonists developed by our group. In one set
of compounds, suitable chelators were coupled at the N-terminal of the potent GRPR-antagonist
[DPhe6,Leu13-NHEt]BBN(6-13) via different linkers allowing for labeling with 99mTc, 68Ga, 111In and
177Lu [15,16,22]. As expected, the resultant radiotracer uptake in PC-3 xenografts in mice was found
to depend on in vivo stability. The latter was influenced by structural changes of the radiotracer
not only on the peptide chain, but also the linker or the radiometal chelate. For example, in a small
library of 99mTc-DB1 mimics [22], the DAla11-substituted analog was the most in vivo robust member,
in agreement with the higher stability reported for similarly substituted DAla11/Gly11-BBN-like or
DAla24/Gly24-GRP-like analogs [21]. In another example, it was the radiometal/radiometal-chelate
affecting in vivo stability and tumor uptake. Thus, by switching radiometal from 68Ga to 111In (or 177Lu)
in SB3 we observed a drastic drop of metabolic stability translating into impaired targeting of 111In-SB3
PC-3 tumors in mice compared to 68Ga-SB3 [17,18].
In an effort to identify the major protease(s) involved in the fast in vivo degradation of radiolabeled
[DPhe6,Leu13-NHEt]BBN(6-13) analogs, we have co-injected specific protease-inhibitors along with the
radiopeptide and applied HPLC analysis to monitor potential changes in radiometabolite patterns induced
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in mouse blood [17,23]. Of great significance is the finding that coinjection of the NEP-inhibitor PA stabilized
most GRPR-radioantagonists in vivo, leading to remarkable enhancement of radiolabel uptake in the
implanted PC-3 tumors. The above results established NEP as a leading cause of in vivo catabolism of
studied radioligands. Furthermore, the innovative concept of enhancing tumor targeting via in-situ altering
the immediate milieu of the radiopeptide on its way to the target instead of modifying its structure warrants
further investigation.
In the present study we first introduced SB4, a single DAla11/Gly11-substution derivative of SB3.
This modification was shown to enhance radiotracer stability without greatly impairing other biological
features (e.g. receptor affinity or in vivo tumor targeting) in a series of 99mTc-DB1 mimics [22]. In the
present study however, we observed a ≈2.5-fold drop of affinity to the GRPR by comparing SB3 (IC50
= 4.6 ± 0.3 nM, n=3) to SB4 (IC50 = 11.2 ± 1.1 nM, n = 3; p < 0.001). We have not compared the receptor
affinities of the In-metalated species, given that the type and position of the forming metal-chelate
was identical in the two analogs, which differed only at position 11 of the peptide chain. Furthermore,
the overall specific uptake of the respective 111In-radioltracers in PC-3 cells after 1 h incubation at
37 oC significantly dropped from 16.2 ± 0.8% (111In-SB3) to 1.9 ± 0.5% (111In-SB4) of total added
activity (p < 0.0001). This drop followed the same trend of receptor affinity deterioration observed
in the unlabeled species and further corroborated the negative effect of DAla11/Gly11-substution on
the in vitro interaction of SB4/111In-SB4 with the GRPR (Figure 2). However, the in vivo stability
of 111In-SB4 in peripheral mouse blood (80 ± 3% intact, n = 3) was found significantly increased
compared to 111In-SB3 (56 ± 2% intact, n = 3; p < 0.001) (Figure 3). It is interesting to note that
the pursued DAla11/Gly11-replacement, albeit improving in vivo stability, negatively influenced the
interaction with the GRPR, eventually translating into poorer uptake of 111In-SB4 in PC-3 tumors in
mice (Figure 4). At both the 4 h and the 24 h pi time intervals unmodified 111In-SB3 (8.8 ± 3.0%ID/g
and 4.4± 0.3%ID/g, respectively) showed superior uptake compared to 111In-SB4 (3.0± 0.8%ID/g and
0.9± 0.1%ID/g, respectively; p < 0.01), revealing the negative impact of this modification on the overall
performance of resulting radiotracer. This unfavorable result was found to be surprisingly pronounced
in the 111In-SB3/111In-SB4 pair compared to what was expected from previous observations on other
analogs [21] and highlights the fact that extrapolation of structural changes across molecules may lead
to different or even opposite effects.
Aiming at assessing the impact of the alternative NEP-inhibition approach on the in vivo
performance of 111In-SB3 and 111In-SB4, we have co-injected PA and studied the changes induced on
the in vivo stability and tumor uptake of both radioligands at 4 h pi. Firstly, we observed an impressive
full stabilization of both radiotracers in mice blood (Figure 3). Most importantly, this stabilization
translated into remarkably enhanced tumor values for both non-modified 111In-SB3 (38.3 ± 7.9%ID/g;
p < 0.001) and the DAla11/Gly11-modified 111In-SB4 (7.3 ± 0.3%ID/g; p < 0.001). It is clearly evident
that in-situ NEP-inhibition is a direct and more effective strategy than structural intervention to
improve tumor targeting in this pair of GRPR-radioantagonists.
However, several issues need to be addressed first before proposing this exciting approach for
clinical application of GRPR-radioantagonists or of a broader spectrum of peptide analogs. Thus,
protease-inhibitor administration as such or in combination with the radiopeptide in question has to
be proven safe for patients. Next, the increased costs of extended toxicology tests and production of
GMP-grade compounds for clinical testing should be taken into account. Eventually, it is expected
that approval by ethical committees will become more challenging when injection of combinations of
substances is planned. On the other hand, the in situ protease-inhibition concept, once clinically
established for a certain radiopeptide, may be more easily extrapolated thereafter to a broader
spectrum of radiopeptide candidates for clinical translation. Undoubtedly, this methodology provides
a powerful preclinical tool to: (i) identify enzymes truly involved in the degradation of biodegradable
peptide radioligands, (ii) reveal cleavage sites and (iii) indicate the range of feasible improvements for
a particular tumor-target model induced by radiopeptide stabilization.
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4. Materials and Methods
4.1. Peptides and Radioligands
The SB3 (DOTA-p-aminomethylaniline-diglycolic acid-DPhe-Gln-Trp-Ala-Val-Gly-His- Leu-
NHEt) and SB4 (DOTA-p-aminomethylaniline-diglycolic acid-DPhe-Gln-Trp-Ala-Val-DAla-His-
Leu-NHEt; Figure 1) peptide conjugates were synthesized on the solid support as previously
reported [17] and were provided by PiChem (Graz, Austria). The [Tyr4]BBN (Tyr4-bombesin,
Pyr-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2) reference was purchased from
PSL GmbH (Heidelberg, Germany).
Radioiodination of [Tyr4]BBN was performed using 125I ([125I]NaI in 0.1 N NaOH (pH 12–14)
provided by Perkin Elmer) according to the chloramine-T methodology, as previously described [22].
The forming sulfoxide (Met14=O) was reduced by dithiothreitol and [125I-Tyr4]BBN was isolated in
non-carrier added form by HPLC. Methionine was added to the purified radioligand solution to
prevent re-oxidation of Met14 to the corresponding sulfoxide and the resulting stock solution in 0.1%
BSA-PBS was kept at −20 ◦C; aliquots thereof were used in competition binding assays (molar activity
of 2.2 Ci/µmol).
Preparation and Quality Control of 111In-SB3 and 111In-SB4
Lyophilized SB3 or SB4 was dissolved in HPLC-grade H2O (2 mg/mL) and 50 µL aliquots thereof
were stored in Eppendorf Protein LoBind tubes at −20 ◦C. For labeling, 111InCl3 in 50 mM HC1
(activity concentration of 0.37 GBq/mL on calibration date) was employed (Mallinckrodt Medical
B.V., Petten, The Netherlands). In Eppendorf Protein LoBind tubes (1.5 mL capacity) 111InCl3 solution
(150 µL, 55–110 MBq) was mixed with SB3 or SB4 (15 nmol), 1 M sodium acetate buffer pH 4.6 (20 µL)
was added and the mixture was left to react at 85 ◦C for 20 min. For in vivo studies 111In-SB3 and
111In-SB4 were obtained at molar activities of 3.7–7.4 MBq 111In/nmol DOTA-conjugate.
Reversed-phase HPLC was performed on a Waters Chromatograph based on a 600E multisolvent
delivery system coupled to a Waters 2998 photodiode array detector and a Gabi gamma-detector
(Raytest, RSM Analytische Instrumente GmbH). Data processing and chromatography were controlled
by the Empower Software (Waters, Vienna, Austria). For quality control 2 µL aliquots of the
radiolabeling solution were quenched with 28 µL of an acetate buffered solution of DTPA (1 mM,
pH 4.6) and a Symmetry Shield RP18 cartridge column (5 µm, 3.9 mm × 20 mm, Waters) was used
for analyses. Solutes were eluted with 0.1% TFA/MeCN applying a linear gradient starting from
0% MeCN and a 2% increase per min at 1 mL/min flow rate (system 1). The radiochemical labeling
yield exceeded 98% and the radiochemical purity was >99%. Samples of 111In-SB3 and 111In-SB4 were
analyzed before and after completion of all biological experiments.
4.2. In Vitro Assays
4.2.1. Cell Lines and Culture
Human androgen-independent prostate adenocarcinoma PC-3 cells endogenously expressing
the human GRPR (LGC Promochem, Teddington, UK) were used in the present study [24]. Cells
were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium, supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin and 100 µg/mL streptomycin, and kept
in a controlled humidified atmosphere containing 5% CO2 at 37 ◦C. Passages were performed weekly
using a trypsin/EDTA (0.05%/0.02% w/v) solution. All culture media were purchased from Gibco
BRL, Life Technologies and supplements were provided by Biochrom KG Seromed.
4.2.2. Competition Binding in PC-3 Cell-Membranes
Competition binding experiments against [125I-Tyr4]BBN were performed with SB3, SB4,
or [Tyr4]-BBN (reference) in PC-3 cell membranes, prepared as previously reported [25]. For the
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assay, triplicates per concentration point (concentration range: 10−13–10−6 M) of each test peptide were
incubated together with the radioligand (~40,000 cpm per assay tube, at a 50 pM concentration) in PC-3
cell-membrane homogenates in a total volume of 300 µL binding buffer (BB, 50 mM HEPES pH 7.4, 1%
BSA, 5.5 mM MgCl2, 35 µM bacitracin) for 1 h at 22 ◦C in an Incubator-Orbital Shaker (MPM Instr. SrI,
Italy). Binding was interrupted by ice-cold washing buffer (WB, 10 mM HEPES pH 7.4, 150 mM NaCl)
and rapid filtration (Whatman GF/B filters presoaked in BB) on a Brandel Cell Harvester (Adi Hassel
Ing. Büro, Munich, Germany). Filters were washed with ice-cold WB and counted in an automatic
well-type gamma counter (NaI(Tl) 3´´-crystal, Cobra Packard Auto-Gamma 5000 series instrument).
The half maximal inhibitory concentration (IC50) values were calculated using nonlinear regression
according to a one-site model applying the PRISM 2 program (Graph Pad Software, San Diego, CA)
and represent the mean±sd from three independent experiments performed in triplicate.
4.2.3. Internalization Assay in PC-3 Cells
The overall cell association – internalization of 111In-SB3 and 111In-SB4 was assessed in PC-3
cells. Briefly, PC-3 cells were seeded in six-well plates (~1 × 106 cells per well) 24 h before the
experiment. Approximately 50,000 cpm of either 111In-SB3 or 111In-SB4 (corresponding to 250 fmol
total peptide in 150 µL of 0.5% BSA/PBS) was added alone (total) or in the presence of 1 µM [Tyr4]BBN
(non-specific). Cells were incubated at 37 ◦C for 1 h and incubation was interrupted by placing the
plates on ice, removing the supernatants and rapid rinsing with ice-cold 0.5% BSA/PBS. Cells were
then treated 2 × 5 min with acid wash buffer (2 × 0.6 mL, 50 mM glycine buffer pH 2.8, 0.1 M NaCl) at
room temperature and supernatants were collected (membrane-bound fraction). After rinsing with
1 mL chilled 0.5% BSA/PBS, cells were lyzed by treatment with 1 N NaOH (2 × 0.6 mL) and lysates
were collected (internalized fraction). Sample radioactivity was measured in the γ-counter and total
cell-associated (internalized+membrane bound) radioactivity was determined vs. total added activity.
Results represent the average values ± sd of four experiments performed in triplicate.
4.3. Animal Studies
4.3.1. In Vivo Stability Tests
For stability experiments (approved protocol # 1609, Prefecture of Attica), healthy male Swiss
albino mice (30 ± 5 g, NCSR “Demokritos” Animal House Facility) were used. The radioligand,
111In-SB3 or 111In-SB4, was injected as a 100 µL bolus (11–22 MBq, 3 nmol total peptide) in the tail vein
together with injection solution (100 µL; control) or with a phosphoramidon (PA)-solution (100 µL
injection solution containing 300 µg PA). Animals were euthanized and blood (0.5–1 mL) was directly
withdrawn from the heart and transferred in a pre-chilled EDTA-containing Eppendorf tube on ice.
Blood samples were centrifuged for 10 min at 2000 g/4 ◦C and plasma was collected. After addition
of an equal volume of ice-cold MeCN the mixture was centrifuged for 10 min at 15,000 g/4 ◦C.
The supernatant was concentrated under a N2-flux at 40 ◦C to 0.05-0.1 mL, diluted with saline (0.4 mL),
filtered through a 0.22 µm Millex GV filter (Millipore, Milford, USA) and analyzed by RP-HPLC.
The Symmetry Shield RP18 (5 µm, 3.9 mm × 20 mm) column was eluted at a flow rate of 1.0 mL/min
with the following linear gradient (system 2): 0% B at 0 min to 10% B in 10 min and then in 40 min to
30% B; A = 20 mM ammonium acetate and B = MeCN. The tR of the intact radiopeptide was determined
by coinjection with the 111In-SB3 or 111In-SB4 reference in the HPLC.
4.3.2. Induction of PC-3 Xenografts in SCID Mice
A suspension containing freshly harvested human PC-3 cells (≈150 µL of a ≈1.2 × 107 cells) was
subcutaneously injected in the flanks of female SCID mice (15 ± 3 g, six weeks of age at the day of
arrival, NCSR “Demokritos” Animal House Facility). The animals were kept under aseptic conditions
and 4 weeks later developed well-palpable tumors (80–200 mg) at the inoculation sites (approved
protocol # 1610, Prefecture of Attica).
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4.3.3. Biodistribution in PC-3 Xenograft-Bearing SCID Mice
For the biodistribution study (approved protocol # 1610, Prefecture of Attica), animals in groups
of 4 received via the tail vein a 100 µL bolus of 111In-SB3 or 111In-SB4 (37 kBq, corresponding to 10 pmol
total peptide) co-injected either with injection solution (100 µL; control) or PA-solution (300 µg PA
dissolved in 100 µL injection solution; 4 h + PA), or with excess [Tyr4]BBN (100 µL injection solution
containing 50 µg [Tyr4]BBN for in vivo GRPR-blockade; 4 h block). Animals were euthanized at
4 and 24 h pi and dissected; samples of blood, tumors and organs of interest were collected, weighed
and measured for radioactivity in the gamma counter. Intestines and stomach were not emptied of
their contents. Data was calculated as percent injected dose per gram tissue (%ID/g) with the aid of
standard solutions and represent mean values±sd, n = 4.
4.4. Statistical Analyses
The unpaired two tailed Student’s t test or one-way ANOVA with Tukey’s post-hoc analysis of
GraphPad Prism Software (San Diego, CA) was applied to determine statistically significant differences.
p values of <0.05 were considered to be statistically significant.
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